InterCure (INCR)
(Delayed Data from NSDQ)
$2.48 USD
+0.09 (3.77%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $2.42 -0.06 (-2.42%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
INCR 2.48 +0.09(3.77%)
Will INCR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INCR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for INCR
Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ
Intercure Ltd. Files SEC Report, Ensures Transparency
InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference
CRVS, CTMX and NRXP are among premarket gainers
InterCure Reports Strong FY2023: Performance Paves the Way for Global Expansion